GlassScriptPhysician profile
Matthew T Dorman
NPI 1740284439
$10,453.49
in general payments reported to CMS, 2019-2025
60 companies · $1,822 in 2025
The $1,822 reported for 2025 was more than what 94% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,055 · 2020: $1,130 · 2021: $1,691 · 2022: $1,486 · 2023: $1,757 · 2024: $1,513 · 2025: $1,822.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,092.46 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,582.14 | 2020-2025 | Ubrelvy, Qulipta, Vraylar |
| Novo Nordisk INC | $1,318.34 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $1,018.99 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $560.37 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $532.73 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $500.39 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $334.93 | 2019-2025 | Xifaxan |
| Amarin Pharma, INC. | $332.20 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $331.50 | 2019-2024 | |
| Abbott Laboratories | $330.92 | 2021-2025 | Freestyle Libre 3, Proclaim |
| Otsuka America Pharmaceutical, INC. | $284.42 | 2020-2023 | Rexulti |
| Janssen Pharmaceuticals, INC | $258.11 | 2020-2024 | Spravato |
| Astellas Pharma US INC | $201.53 | 2019-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $194.69 | 2019-2024 | Jardiance |
| Lundbeck LLC | $179.96 | 2023-2025 | Rexulti |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Dorman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.